Teva Pharmaceutical Industries Limited
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B | $2.18B | $1.98B | $1.78B |
| Accounts Receivable | $3.71B | $3.06B | $3.41B | $3.70B | $4.53B | $4.58B | $5.68B | $5.82B |
| Inventory | $3.18B | $3.01B | $4.02B | $3.83B | $3.82B | $4.40B | $4.42B | $4.73B |
| Total Current Assets | $13.95B | $12.55B | $12.49B | $12.05B | $12.57B | $13.01B | $13.46B | $13.79B |
| Property, Plant & Equipment | $4.08B | $4.58B | $5.75B | $5.74B | $5.98B | $6.30B | $6.44B | $6.87B |
| Goodwill | $16.00B | $15.15B | $17.18B | $17.18B | $17.63B | $20.62B | $24.85B | $24.92B |
| Intangible Assets (Excl. Goodwill) | $3.78B | $4.42B | $5.39B | $6.27B | $7.47B | $8.92B | $11.23B | $14.01B |
| Total Assets | $40.75B | $39.33B | $43.48B | $44.01B | $47.67B | $50.64B | $57.47B | $60.68B |
| Liabilities | ||||||||
| Accounts Payable | $225.0M | $158.0M | $108.0M | $1.89B | $1.69B | $1.76B | $1.72B | $1.85B |
| Total Current Liabilities | $13.46B | $12.80B | $12.25B | $11.47B | $11.03B | $13.16B | $13.67B | $14.32B |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $32.83B | $33.61B | $35.35B | $35.41B | $36.42B | $39.58B | $42.41B | $44.89B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-13.76B | $-15.17B | $-13.53B | $-12.98B | $-10.53B | $-10.95B | $-6.96B | $-5.96B |
| Total Stockholders' Equity | $7.91B | $5.37B | $7.51B | $7.80B | $10.28B | $10.03B | $13.97B | $14.71B |